JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma regains China rights to Nerlynx and amends deal with Fabre
Reducing Recurrence
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Mission Accomplished – 365 Days on Nerlynx – Ela K. Browder
Nerlynx (neratinib) for the Treatment of Breast Cancer
News Release
NERLYNX (neratinib) RATIONALE FOR INCLUSION IN PA PROGRAM
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | Fierce Pharma
Puma Biotechnology
Puma Biotechnology Files NDS For NERLYNX In Canada
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
HER2+ Breast Cancer Patient and Caregiver Support
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX. NERLYNX ® (neratinib) tablets, for oral use Initial U.S. Approval: 2017
Puma Biotechnology breast cancer drug approved in EU | S&P Global Market Intelligence
Neratinib Chapter
